Therapeutic efficacy of telbivudine for treating chronic hepatitis B patients with elevated levels of serum soluble E-selectin
-
摘要:
目的观察替比夫定(LdT)治疗前后慢性乙型肝炎(CHB)患者HBsAg水平和血清中可溶性E选择素(sE-selectin)含量的变化。方法 107例CHB患者给予口服LdT 600 mg/d治疗,观察治疗前、治疗后第12、24和48周时患者HBsAg水平和血清中sE-selectin含量的变化,并进行相关性分析。结果 CHB患者血清sE-selectin含量明显高于健康对照组(P<0.01)。与治疗前相比,107例患者经LdT治疗后HBsAg水平和血清中sE-selectin含量均明显降低(P<0.01)。相关性分析表明,HBsAg水平和血清sE-selectin含量呈正相关(P<0.01)。结论 LdT可通过降低CHB患者血清中sE-selectin水平,提高免疫功能来抑制HBV复制。
Abstract:Objective To compare the levels of hepatitis B surface antigen (HBsAg) and serum soluble (s) E-selectin before and after telbivudine (LdT) treatment in patients with chronic hepatitis B (CHB) .Methods One-hundred-and-seven patients with CHB and 82 healthy controls were enrolled in the study.The levels of HBsAg and serum sE-selectin were measured by enzyme-linked immunosorbent assay (ELISA) before and after LdT treatment.The correlation between HBsAg and serum sE-selectin was analyzed by Pearson′s correlation analysis.Results The pre-treatment sE-selectin content of the CHB group was significantly higher than that of the healthy control group (P<0.01) .The levels of both HBsAg and sE-selectin were significantly reduced in the CHB group after treatment with LdT (P<0.01) .The correlation analysis showed that the HBsAg level was positively correlated with the content of sE-selectin (P<0.01) .Conclusion sLdT may inhibit HBV replication by decreasing the serum sE-selectin content, which may lead to an enhanced immune function.
-
Key words:
- telbivudine /
- hepatitis B /
- chronic
-
[1]朱传武, 王海燕, 李明, 等.干扰素治疗慢性乙型肝炎与外周血树突状细胞表型的关系[J].中华肝脏病杂志, 2004, 12 (3) :51-52. [2]祝先进, 宋艳芳, 曹颖平, 等.慢性乙型肝炎患者外周血趋化因子CXCL10和CXCL11的表达及意义[J].临床肝胆病杂志, 2011, 27 (8) :804-806. [3]Wu S, Zhou X, Yang H, et al.Polymorphisms and plasma solublelevels of E-selectin in patients with chronichepatitis B virus infec-tion[J].Clin Chem Lab Med, 2009, 47 (2) :159-164. [4]Yan MX, Mao HT, Liu Q, et al.Elevated levels of serum soluble E-selectin in patients with chronic hepatitis B:Correlation with Tlymphocyte subsets, NK cells and liver inflammation[J].HepatolRes, 2006, 35 (2) :111-117. [5]罗生强.替比夫定治疗慢性乙型肝炎的新进展[J].中国新药杂志, 2008, 17 (8) :625-629. [6]赵文莉, 王保春, 黄飞.替比夫定治疗乙型肝炎肝硬化患者48周临床观察[J].临床肝胆病杂志, 2011, 27 (8) :840-843. [7] 中华医学会肝病学分会, 中华医学会感染学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :I-XVI. [8]吴小宁, 徐丹.拉米夫定对慢性乙型肝炎患者白细胞介素-6和肝纤维化指标的影响[J].中国现代医学杂志, 2011, 21 (22) :2780-2782. [9]Liaw YF, Gane E, Leung N, et al.2-Year GLOBE trial results:telbivudine Is superior to lamivudine in patientswith chronic hepati-tis B[J].Gastroenterology, 2009, 136 (2) :486-495. [10]Hou J, Yin YK, Xu D, et al.Telbivudine versus lamivudine inChinese patients with chronic hepatitis B:Results at 1 year of a ran-domized, double-blind trial[J].Hepatology, 2008, 47 (2) :447-454. [11]蔡伟娟, 陈慧园, 程江.E-选择素在肝脏疾病中的研究进展[J].临床荟萃, 2011, 26 (13) :1192-1195.
计量
- 文章访问数: 2778
- HTML全文浏览量: 10
- PDF下载量: 634
- 被引次数: 0